{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:25:46Z","timestamp":1792095946869,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/bjc.2017.62","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T21:00:56Z","timestamp":1489525256000},"page":"1126-1134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers"],"prefix":"10.1038","volume":"116","author":[{"given":"Eric","family":"Angevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Isambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Trillet-Lenoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Vielh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Farace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Valleix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Podoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kuramochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikao","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"BFbjc201762_CR1","first-page":"1369","volume":"26","author":"VJ Amatya","year":"2011","unstructured":"Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, Inai K (2011) Overexpression of CD26\/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncol Rep 26: 1369\u20131375.","journal-title":"Oncol Rep"},{"key":"BFbjc201762_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1158\/1078-0432.CCR-11-1990","volume":"18","author":"K Aoe","year":"2012","unstructured":"Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C (2012) CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res 18: 1447\u20131456.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201762_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/ni.3201","volume":"16","author":"R Barreira da Silva","year":"2015","unstructured":"Barreira da Silva R, Laird ME, Yatim N, Fiette L, Ingersoll MA, Albert ML (2015) Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol 16: 850\u2013858.","journal-title":"Nat Immunol"},{"key":"BFbjc201762_CR4","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","volume":"48","author":"JK Blayney","year":"2012","unstructured":"Blayney JK, Ceresoli GL, Castagneto B, O\u2019Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O\u2019Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA (2012) Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer 48: 2983\u201329892.","journal-title":"Eur J Cancer"},{"key":"BFbjc201762_CR5","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.4049\/jimmunol.144.11.4092","volume":"144","author":"NH Dang","year":"1990","unstructured":"Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C (1990a) Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 144: 4092\u20134100.","journal-title":"J Immunol"},{"key":"BFbjc201762_CR6","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.4049\/jimmunol.145.12.3963","volume":"145","author":"NH Dang","year":"1990","unstructured":"Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C (1990b) Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 145: 3963\u20133971.","journal-title":"J Immunol"},{"key":"BFbjc201762_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.biopha.2015.02.031","volume":"71","author":"S Davies","year":"2015","unstructured":"Davies S, Beckenkamp A, Buffon A (2015) CD26 a cancer stem cell marker and therapeutic target. Biomed Pharmacother 71: 135\u2013138.","journal-title":"Biomed Pharmacother"},{"key":"BFbjc201762_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0161-5890(98)80013-8","volume":"35","author":"RP Dong","year":"1998","unstructured":"Dong RP, Tachibana K, Hegen M, Scharpe S, Cho D, Schlossman SF, Morimoto C (1998) Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. Mol Immunol 35: 13\u201321.","journal-title":"Mol Immunol"},{"key":"BFbjc201762_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2010.12.054","volume":"404","author":"FI Ghani","year":"2011","unstructured":"Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, Mimura Y, Fujimoto N, Kishimoto T, Yamada T, Xu CW, Morimoto C (2011) Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun 404: 735\u2013742.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbjc201762_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1746-1596-9-30","volume":"9","author":"R Hatano","year":"2014","unstructured":"Hatano R, Yamada T, Matsuoka S, Iwata S, Yamazaki H, Komiya E, Okamoto T, Dang NH, Ohnuma K, Morimoto C (2014) Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol 9: 30.","journal-title":"Diagn Pathol"},{"key":"BFbjc201762_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.4049\/jimmunol.1402143","volume":"194","author":"R Hatano","year":"2015","unstructured":"Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, Dang NH, Okumura K, Morimoto C (2015) CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol 194: 960\u2013972.","journal-title":"J Immunol"},{"key":"BFbjc201762_CR12","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.2741\/2787","volume":"13","author":"PA Havre","year":"2008","unstructured":"Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH (2008) The role of CD26\/dipeptidyl peptidase IV in cancer. Front Biosci 13: 1634\u20131645.","journal-title":"Front Biosci"},{"key":"BFbjc201762_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2567.1997.00053.x","volume":"90","author":"M Hegen","year":"1997","unstructured":"Hegen M, Kameoka J, Dong RP, Schlossman SF, Morimoto C (1997) Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 90: 257\u2013264.","journal-title":"Immunology"},{"key":"BFbjc201762_CR14","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P (2014) Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 123: 3951\u20133962.","journal-title":"Blood"},{"key":"BFbjc201762_CR15","first-page":"2031","volume":"7","author":"L Ho","year":"2001","unstructured":"Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH (2001) In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7: 2031\u20132040.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201762_CR16","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-06-0361","volume":"12","author":"T Inamoto","year":"2006","unstructured":"Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH, Morimoto C (2006) Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27kip1 enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 12: 3470\u20133477.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201762_CR17","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","volume":"13","author":"T Inamoto","year":"2007","unstructured":"Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C (2007) Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 13: 4191\u20134200.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201762_CR18","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.143.11.3430","volume":"143","author":"C Morimoto","year":"1989","unstructured":"Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, Letvin NL, Schlossman SF (1989) 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 143: 3430\u20133439.","journal-title":"J Immunol"},{"key":"BFbjc201762_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-065X.1998.tb01571.x","volume":"161","author":"C Morimoto","year":"1998","unstructured":"Morimoto C, Schlossman SF (1998) The structure and function of CD26 in the T-cell immune response. Immunol Rev 161: 55\u201370.","journal-title":"Immunol Rev"},{"key":"BFbjc201762_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, Ohashi PS (2015) Clinical blockade of PD1 and LAG3\u2014potential mechanisms of action. Nat Rev Immunol 15: 45\u201356.","journal-title":"Nat Rev Immunol"},{"key":"BFbjc201762_CR21","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3892\/ol.2015.3063","volume":"9","author":"S Nishikawa","year":"2015","unstructured":"Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Fukusumi T, Satoh T, Takiguchi S, Mori M, Doki Y, Ishii H (2015) Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26. Oncol Lett 9: 2361\u20132367.","journal-title":"Oncol Lett"},{"key":"BFbjc201762_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","volume":"29","author":"K Ohnuma","year":"2008","unstructured":"Ohnuma K, Dang NH, Morimoto C (2008) Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 29: 295\u2013301.","journal-title":"Trends Immunol"},{"key":"BFbjc201762_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/B978-0-12-385855-9.00003-5","volume":"53","author":"K Ohnuma","year":"2011","unstructured":"Ohnuma K, Hosono O, Dang NH, Morimoto C (2011) Dipeptidyl peptidase in autoimmune pathophysiology. Adv Clin Chem 53: 51\u201384.","journal-title":"Adv Clin Chem"},{"key":"BFbjc201762_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/jcla.21736","volume":"29","author":"K Ohnuma","year":"2015","unstructured":"Ohnuma K, Saito T, Hatano R, Hosono O, Iwata S, Dang NH, Ninomiya H, Morimoto C (2015a) Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum. J Clin Lab Anal 29: 106\u2013111.","journal-title":"J Clin Lab Anal"},{"key":"BFbjc201762_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ni.3210","volume":"16","author":"K Ohnuma","year":"2015","unstructured":"Ohnuma K, Hatano R, Morimoto C (2015b) DPP4 in anti-tumor immunity: going beyond the enzyme. Nat Immunol 16: 791\u2013792.","journal-title":"Nat Immunol"},{"key":"BFbjc201762_CR26","doi-asserted-by":"publisher","first-page":"e86671","DOI":"10.1371\/journal.pone.0086671","volume":"9","author":"T Okamoto","year":"2014","unstructured":"Okamoto T, Iwata S, Yamazaki H, Hatano R, Komiya E, Dang NH, Ohnuma K, Morimoto C (2014) CD9 Negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells. PLoS ONE 9: e86671.","journal-title":"PLoS ONE"},{"key":"BFbjc201762_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.stem.2010.04.001","volume":"6","author":"R Pang","year":"2010","unstructured":"Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT, Wong BC (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6: 603\u2013615.","journal-title":"Cell Stem Cell"},{"key":"BFbjc201762_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12: 278\u2013287.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc201762_CR29","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.90.10.4586","volume":"90","author":"T Tanaka","year":"1993","unstructured":"Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C (1993) The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 90: 4586\u20134590.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc201762_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0161-5890(92)90099-J","volume":"29","author":"Y Torimoto","year":"1992","unstructured":"Torimoto Y, Dang NH, Tanaka T, Prado C, Schlossman SF, Morimoto C (1992) Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol Immunol 29: 183\u2013192.","journal-title":"Mol Immunol"},{"key":"BFbjc201762_CR31","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP van Meerbeeck","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881\u20136889.","journal-title":"J Clin Oncol"},{"key":"BFbjc201762_CR32","doi-asserted-by":"publisher","first-page":"e62304","DOI":"10.1371\/journal.pone.0062304","volume":"8","author":"K Yamada","year":"2013","unstructured":"Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T (2013) Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One 8: e62304.","journal-title":"PLoS One"},{"key":"BFbjc201762_CR33","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/bjc.2014.151","volume":"110","author":"J Yamamoto","year":"2014","unstructured":"Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C (2014) Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma. Br J Cancer 110: 2232\u20132245.","journal-title":"Br J Cancer"},{"key":"BFbjc201762_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbrc.2012.02.054","volume":"419","author":"H Yamazaki","year":"2012","unstructured":"Yamazaki H, Naito M, Ghani FI, Dang NH, Iwata S, Morimoto C (2012) Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells. Biochem Biophys Res Commun 419: 529\u2013536.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201762","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:41:13Z","timestamp":1692722473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFbjc201762"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.62","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]},"assertion":[{"value":"8 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yutaro Kaneko is an employer of Y\u2019s AC Co., Ltd, Japan, Thomas Podoll is an employer of Y\u2019s Therapeutics Inc., USA, and Yu Kuramochi and Itaru Miyashita are the employees of Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. Chikao Morimoto, Kei Ohnuma and Nam H Dang are stock holders of Y\u2019s AC Co., Ltd. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}